Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent oral polio vaccine + inactivated polio vaccine + inactivated polio vaccine type 2
- Development stage
- Unknown
- Lead developer
- Aga Khan University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral, Intramuscular
01
Overview
A combination vaccination regimen evaluated by Aga Khan University for the prevention of poliomyelitis. This regimen incorporates bivalent oral polio vaccine (bOPV), which contains live-attenuated Sabin strains of poliovirus types 1 and 3, alongside trivalent inactivated polio vaccine (IPV) and a monovalent inactivated polio vaccine type 2 (IPV2 or mIPV2). The combination is designed to optimize population immunity against all three poliovirus serotypes, specifically addressing the immunity gap for type 2 poliovirus that occurs during the global transition from trivalent oral polio vaccine (tOPV) to bOPV. By combining mucosal immunity from the oral vaccine with systemic immunity from the inactivated vaccines, this strategy aims to prevent paralytic polio and interrupt virus transmission in endemic regions like Pakistan. The regimen was evaluated in Phase 4 clinical trials to assess its immunogenicity against type 2 poliovirus compared to traditional schedules.
- Other names
- bOPV + IPV + IPV2bOPV + IPV + mIPV2bivalent oral polio vaccine + inactivated polio vaccine + inactivated polio vaccine type 2-Aga Khan University-poliomyelitis
Beyond the preview
Go deeper on bivalent oral polio vaccine + inactivated polio vaccine + inactivated polio vaccine type 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent oral polio vaccine + inactivated polio vaccine + inactivated polio vaccine type 2.